 |
274 Diseases |  |
1060 Trials |
|
1060 Trials |  |
12189 News |  |
| «12345678910111213...178179» |
- | Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
Journal: ASO Visual Abstract: Results of a Randomized Clinical Study of Gemcitabine Plus Nab-Paclitaxel versus Gemcitabine Plus S-1 as Neoadjuvant Chemotherapy for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma (RCT, CSGO-HBP-015). (Pubmed Central) - May 26, 2024
No abstract available
- narmafotinib (AMP945) / Amplia Therap
Pulsed priming with narmafotinib enhances both gemcitabine/Abraxane & FOLFIRINOX response in pancreatic cancer (Poster and Exhibition Hall) - May 26, 2024 - Abstract #EACR2024EACR_772;
- | cisplatin / Generic mfg., albumin-bound paclitaxel / Generic mfg.
Enrollment closed, Enrollment change, Trial completion date, Metastases: Nab-PIPAC: PIPAC With Nab-paclitaxel and Cisplatin in Peritoneal Carcinomatosis (clinicaltrials.gov) - May 23, 2024
P1, N=18, Active, not recruiting, Sponsor: University Hospital, Geneva
No abstract available Recruiting --> Active, not recruiting | N=36 --> 18 | Trial completion date: Mar 2024 --> Dec 2024
- ||| quemliclustat (AB680) / Arcus Biosci, Gilead
Enrollment open, Combination therapy: ARC-8: A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies (clinicaltrials.gov) - May 23, 2024
P1, N=195, Recruiting, Sponsor: Arcus Biosciences, Inc.
Recruiting --> Active, not recruiting | N=36 --> 18 | Trial completion date: Mar 2024 --> Dec 2024 Active, not recruiting --> Recruiting
- | cisplatin / Generic mfg., albumin-bound paclitaxel / Generic mfg.
New P2 trial, Metastases: Nab-Paclitaxel Plus Cisplatin With Concurrent Radiotherapy for Patients With Locally Advanced Cervical Cancer: A Multicentre, Single-arm, Phase II Trial. (clinicaltrials.gov) - May 23, 2024
P2, N=64, Not yet recruiting, Sponsor: Peking University Third Hospital
- | Kaitanni (cadonilimab) / Akesobio
New P2 trial: A Study of Cadonilimab?AK104?Combined With Standard Treatment for Function Preservation in Urinary System Tumors (clinicaltrials.gov) - May 22, 2024
P2, N=40, Not yet recruiting, Sponsor: Tongji Hospital
- | Enrollment open, Metastases: PTCA199-11: Radiotherapy to Patients With CA19-9-elevated Advanced Pancreatic Cancer (clinicaltrials.gov) - May 22, 2024
P3, N=210, Recruiting, Sponsor: Fudan University
Active, not recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Enrollment change, Trial termination: QUILT-3.070:Pancreatic Cancer Vaccine: Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy (clinicaltrials.gov) - May 22, 2024
P1/2, N=4, Terminated, Sponsor: ImmunityBio, Inc.
Not yet recruiting --> Recruiting N=173 --> 4 | Unknown status --> Terminated; Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention
- | adebrelimab (SHR-1316) / Jiangsu Hengrui Pharma
New P2 trial: IRB-2024-106: A Study Comparing Neoadjuvant Chemoimmunotherapy and Immuno-consolidationafter Compared With Immunoconsolidation After Radical Chemoradiotherapy for Stage III Potentially Resectable NSCLC (clinicaltrials.gov) - May 22, 2024
P2, N=92, Recruiting, Sponsor: Zeng Jian
- || Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
Review, Journal: Update on management of pancreatic cancer: a literature review. (Pubmed Central) - May 21, 2024
Radical surgery itself is not enough for prolong survival. The improvement of chemotherapy, target agents and immunotherapy with multidisciplinary approach will be the only solution for improvement of survival outcome and quality of life for patients with pancreatic cancer.
- | Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci
Trial completion date: NeoTENNIS: Neoadjuvant Dose-dense EC Followed by ABX With PD-1 for Triple Negative Breast Cancer Patients (clinicaltrials.gov) - May 21, 2024
P2, N=70, Active, not recruiting, Sponsor: Fudan University
The improvement of chemotherapy, target agents and immunotherapy with multidisciplinary approach will be the only solution for improvement of survival outcome and quality of life for patients with pancreatic cancer. Trial completion date: Dec 2023 --> Dec 2025
- | cisplatin / Generic mfg., albumin-bound paclitaxel / Generic mfg., gemcitabine / Generic mfg.
New P2 trial: Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer (clinicaltrials.gov) - May 20, 2024
P2, N=44, Not yet recruiting, Sponsor: Emory University
- | Tyvyt (sintilimab) / Eli Lilly, Sintbilo (tafolecimab) / Innovent Biologics
New P2 trial, IO biomarker, Metastases: A Prospective, Single-arm, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Tafolecimab and Sintilimab Combined With Chemotherapy in Patients With Advanced or Metastatic Driver Gene-negative Non-small Cell Lung Cancer After Failure of First-line Immunotherapy. (clinicaltrials.gov) - May 20, 2024
P2, N=30, Recruiting, Sponsor: Jinghui Wang
- ||||| spartalizumab (PDR001) / Novartis, nisevokitug (NIS793) / Novartis
Trial termination, Combination therapy, Metastases: daNIS-1: Study of Efficacy and Safety of NIS793 (With and Without Spartalizumab) in Combination With SOC Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) (clinicaltrials.gov) - May 20, 2024
P2, N=164, Terminated, Sponsor: Novartis Pharmaceuticals
Trial completion date: Dec 2023 --> Dec 2025 Active, not recruiting --> Terminated; The study was early terminated following the NIS793 treatment halt and urgent safety measure issued in July 2023, as the continued evaluation of Standard of Care alone will not support the original purpose of this phase 2 clinical trial.
- | Trial completion date, Trial primary completion date, Metastases: GABRINOX-ART: Sequential Treatment With GEMBRAX and Then FOLFIRINOX Followed by Stereotactic MRI-guided Radiotherapy in Patients With Locally Advanced Pancreatic Cancer (clinicaltrials.gov) - May 20, 2024
P2, N=103, Recruiting, Sponsor: Institut du Cancer de Montpellier - Val d'Aurelle
Active, not recruiting --> Terminated; The study was early terminated following the NIS793 treatment halt and urgent safety measure issued in July 2023, as the continued evaluation of Standard of Care alone will not support the original purpose of this phase 2 clinical trial. Trial completion date: Oct 2026 --> Jun 2030 | Trial primary completion date: Oct 2023 --> Jan 2028
- | adebrelimab (SHR-1316) / Jiangsu Hengrui Pharma
New trial, Metastases: Adebrelimab Combined With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC) (clinicaltrials.gov) - May 20, 2024
P=N/A, N=30, Not yet recruiting, Sponsor: Hebei Medical University Fourth Hospital
- |||||||||| BNT327 / BioNTech
New P3 trial, Combination therapy, Metastases: PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic Triple-negative Breast Cancer (clinicaltrials.gov) - May 20, 2024
P3, N=360, Not yet recruiting, Sponsor: Biotheus Inc.
- |||||||||| sacituzumab tirumotecan (MK-2870) / Merck (MSD), Keytruda (pembrolizumab) / Merck (MSD)
New P3 trial, Combination therapy, Metastases: U1111-1301-2790: Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023] (clinicaltrials.gov) - May 20, 2024
P3, N=851, Not yet recruiting, Sponsor: Merck Sharp & Dohme LLC
- | cisplatin / Generic mfg., albumin-bound paclitaxel / Generic mfg.
New P2 trial, Surgery, Metastases: Induction Chemoimmunotherapy Combined With Chemoradiotherapy in Esophageal Cancer (clinicaltrials.gov) - May 19, 2024
P2, N=60, Recruiting, Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- | irinotecan / Generic mfg., albumin-bound paclitaxel / Generic mfg., gemcitabine / Generic mfg.
Journal: Failure to Undergo Resection Following Neoadjuvant Therapy for Resectable Pancreatic Cancer: A Secondary Analysis of SWOG S1505. (Pubmed Central) - May 16, 2024
Failure to undergo resection following NT was relatively common among patients with potentially resectable PDAC and associated with worse survival. Although few predictive factors were identified in this secondary analysis of the SWOG S1505 randomized trial, further research must focus on risk factors for severe toxicities during NT that preclude surgical resection so that patient-centered interventions can be delivered or alternate treatment sequencing can be recommended.
- || Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci
Review, Journal, Metastases: TORCHLIGHT trial, brightening the life of more patients with advanced triple-negative breast cancer. (Pubmed Central) - May 16, 2024
TORCHLIGHT trial, as the name of it, like a torch to more patients with advanced TNBC, lighting up their lives. We described the design background of TORCHLIGHT trial and reviewed primary trials of PD-1 or PD-L1 inhibitor in advanced TNBC both domestically and internationally.
- | Fruzaqla (fruquintinib) / Takeda
New trial, Combination therapy, Metastases: Fruquintinib and Albumin-paclitaxel Combined With or Without PD-1 Antibody in 2nd-line Treatment of G/GEJ Adenocarcinoma (clinicaltrials.gov) - May 15, 2024
P=N/A, N=60, Not yet recruiting, Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- | albumin-bound paclitaxel / Generic mfg., gemcitabine / Generic mfg.
Preclinical, Journal: Single Dual-specific Anti-PD-L1/TGF-? Antibody Synergizes with Chemotherapy as Neoadjuvant Treatment for Pancreatic Ductal Adenocarcinoma: a Preclinical Experimental Study. (Pubmed Central) - May 15, 2024
We described the design background of TORCHLIGHT trial and reviewed primary trials of PD-1 or PD-L1 inhibitor in advanced TNBC both domestically and internationally. Our results suggest that the BiTP combinatorial chemotherapy is a promising neoadjuvant therapy for PDAC.
- | cisplatin / Generic mfg., albumin-bound paclitaxel / Generic mfg.
Retrospective data, Journal, Metastases: Efficacy and safety of different chemotherapy regimens concurrent with radiotherapy in the treatment of locally advanced cervical cancer. (Pubmed Central) - May 15, 2024
These findings could provide a reference for the clinical treatment of LACC. However, further prospective studies are needed to verify it.
- | Enrollment closed, Trial completion date, Trial primary completion date, Metastases: Modified FOLFIRINOX Alternated With Biweekly Gemcitabine Plus Nab-Paclitaxel Untreated Pancreatic Cancer (clinicaltrials.gov) - May 15, 2024
P2, N=30, Active, not recruiting, Sponsor: Lyudmyla Berim
However, further prospective studies are needed to verify it. Recruiting --> Active, not recruiting | Trial completion date: Jun 2024 --> Jun 2025 | Trial primary completion date: Jun 2024 --> Sep 2024
- | Tecentriq (atezolizumab) / Roche
Trial completion date, Trial primary completion date: iReP: Predicting Response to Neoadjuvant ATEZOLIZUMAB Plus Carboplatin/Nab Paclitaxel in Resectable Non-squamous NSCLC (clinicaltrials.gov) - May 14, 2024
P2, N=20, Recruiting, Sponsor: University Hospital Heidelberg
Recruiting --> Active, not recruiting | Trial completion date: Jun 2024 --> Jun 2025 | Trial primary completion date: Jun 2024 --> Sep 2024 Trial completion date: Dec 2024 --> Dec 2026 | Trial primary completion date: Dec 2022 --> Nov 2024
- |||| Zynyz (retifanlimab-dlwr) / Incyte
Trial primary completion date, Metastases: POD1UM-304: Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer (clinicaltrials.gov) - May 14, 2024
P3, N=583, Active, not recruiting, Sponsor: Incyte Corporation
Trial completion date: Dec 2024 --> Dec 2026 | Trial primary completion date: Dec 2022 --> Nov 2024 Trial primary completion date: Jun 2024 --> Dec 2023
- | Phase classification, Enrollment change, Trial completion date, Trial primary completion date: Sequential Use of AG and mFOLFIRINOX as Neoadjuvant Chemotherapy for Resectable Pancreatic Cancer (clinicaltrials.gov) - May 14, 2024
P3, N=291, Recruiting, Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
Trial primary completion date: Jun 2024 --> Dec 2023 Phase classification: P2 --> P3 | N=416 --> 291 | Trial completion date: Oct 2024 --> Oct 2026 | Trial primary completion date: Oct 2023 --> Oct 2025
- |||| zilovertamab (UC-961) / Oncternal Therap
Trial primary completion date, Combination therapy, Metastases: Study of B013 and Nab-Paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer (clinicaltrials.gov) - May 14, 2024
P2/3, N=450, Recruiting, Sponsor: Shanghai Jiaolian Drug Research and Development Co., Ltd
Phase classification: P2 --> P3 | N=416 --> 291 | Trial completion date: Oct 2024 --> Oct 2026 | Trial primary completion date: Oct 2023 --> Oct 2025 Trial primary completion date: Mar 2024 --> Dec 2024
- |||||| Sulanda (surufatinib) / Hutchmed
Enrollment open, Metastases: A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer (clinicaltrials.gov) - May 13, 2024
P2/3, N=482, Recruiting, Sponsor: Hutchmed
Trial primary completion date: Mar 2024 --> Dec 2024 Not yet recruiting --> Recruiting
- | AiRuiKa (camrelizumab) / HLB Bio Group, AiRuiYi (fluzoparib) / Jiangsu Hengrui Pharma
New P2 trial, Metastases: Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer (clinicaltrials.gov) - May 13, 2024
P2, N=117, Recruiting, Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- || Irene (pyrotinib) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche
P2 data, Clinical Trial,Phase II, Journal, IO biomarker, Metastases: Efficacy and safety of pyrotinib combined with albumin-bound paclitaxel as first-line treatment for HER2-positive metastatic breast cancer in patients previously treated with adjuvant and/or neoadjuvant trastuzumab therapy: The stage 1 results of a single-arm, phase 2 prospective clinical trial. (Pubmed Central) - May 13, 2024
This study demonstrates that pyrotinib plus albumin-bound paclitaxel as a first-line treatment regimen shows good efficacy and manageable safety for patients who have received adjuvant and/or neoadjuvant trastuzumab for HER2-positive metastatic breast cancer. Besides, a significant association was identified between the expression levels of TLR3 and RET and the PFS in patients.
- || budigalimab (ABBV-181) / AbbVie, revdofilimab (ABBV-368) / AbbVie, giloralimab (ABBV-927) / AbbVie
Trial completion date, Trial primary completion date, Metastases: A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - May 12, 2024
P1, N=150, Active, not recruiting, Sponsor: AbbVie
Besides, a significant association was identified between the expression levels of TLR3 and RET and the PFS in patients. Trial completion date: Nov 2023 --> Sep 2024 | Trial primary completion date: Nov 2023 --> Sep 2024
- || carboplatin / Generic mfg., albumin-bound paclitaxel / Generic mfg.
Review, Journal: Treatment Strategies for Non-Small-Cell Lung Cancer with Comorbid Respiratory Disease; Interstitial Pneumonia, Chronic Obstructive Pulmonary Disease, and Tuberculosis. (Pubmed Central) - May 11, 2024
To date, there is no coherent review article on NSCLC with these pulmonary complications. This review article summarizes the current evidence and discusses future prospects for treatment strategies for NSCLC patients complicated with IP, severe COPD, and TB.
- | Endostar (recombinant human endostatin) / Simcere
Journal: Acute cardiac tamponade after Endostar treatment of non-small cell lung cancer: A case report. (Pubmed Central) - May 10, 2024
This review article summarizes the current evidence and discusses future prospects for treatment strategies for NSCLC patients complicated with IP, severe COPD, and TB. Medical professionals should remain vigilant for the potential, albeit rare, risk of Endostar inducing acute pericardial tamponade, a severe and potentially fatal complication.
- | Keytruda (pembrolizumab) / Merck (MSD)
Trial completion date, Trial primary completion date, Metastases: Study of Pembrolizumab and Single Agent Chemotherapy as First Line Treatment for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer With Eastern Cooperative Oncology Group (ECOG) Performance Status of 2 (clinicaltrials.gov) - May 10, 2024
P1, N=28, Recruiting, Sponsor: University of Rochester
Medical professionals should remain vigilant for the potential, albeit rare, risk of Endostar inducing acute pericardial tamponade, a severe and potentially fatal complication. Trial completion date: Nov 2023 --> Nov 2024 | Trial primary completion date: Nov 2023 --> Nov 2024
- | bemarituzumab (AMG 552) / Amgen
Phase classification, Monotherapy: A Study of Bemarituzumab Monotherapy and Combination With Other Anti-cancer Therapy in SqNSCLC With FGFR2b Overexpression (FORTITUDE-201) (clinicaltrials.gov) - May 10, 2024
P1, N=180, Active, not recruiting, Sponsor: Amgen
Trial completion date: Nov 2023 --> Nov 2024 | Trial primary completion date: Nov 2023 --> Nov 2024 Phase classification: P1b --> P1
- |||||| Enrollment open, Trial initiation date, Surgery: Observation on the Therapeutic Effect of Huaier Granules in the Adjuvant Treatment of Non-small Cell Lung Cancer After Radical Surgery (clinicaltrials.gov) - May 10, 2024
P=N/A, N=240, Recruiting, Sponsor: Liaoning Tumor Hospital & Institute
Phase classification: P1b --> P1 Not yet recruiting --> Recruiting | Initiation date: Dec 2023 --> Mar 2024
- ||| fludarabine IV / Generic mfg., cyclophosphamide / Generic mfg., albumin-bound paclitaxel / Generic mfg.
Enrollment change, Trial completion date, Trial primary completion date, CAR T-Cell Therapy, Metastases: Pan-T Booster Co-expressing MSLN CAR T Cell Therapy in Advanced/Metastatic Solid Tumors (clinicaltrials.gov) - May 10, 2024
P1/2, N=15, Recruiting, Sponsor: Chinese PLA General Hospital
Not yet recruiting --> Recruiting | Initiation date: Dec 2023 --> Mar 2024 N=30 --> 15 | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2024 --> Dec 2025
- | Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
Journal: ASO Author Reflections: Which was the Better Regimen (Gemcitabine Plus Nab-Paclitaxel Versus Gemcitabine Plus S-1) as Neoadjuvant Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma (R/BR-PDAC)? (Pubmed Central) - May 9, 2024
N=30 --> 15 | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2024 --> Dec 2025 No abstract available
- Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca
Trastuzumab deruxtecan (T-DXd) vs physician's choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): Primary results from DESTINY-Breast06 (DB-06). (Hall D1) - May 9, 2024 - Abstract #ASCO2024ASCO_7046;
P3
HER2-ultralow results were consistent with HER2-low. Safety was in line with known profiles.
- | Trial completion date, Trial primary completion date: A Study of Reduced Radiation Therapy and Standard-of-Care Chemotherapy in People With HPV-Positive Throat Cancer (clinicaltrials.gov) - May 9, 2024
P2, N=121, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Safety was in line with known profiles. Trial completion date: Aug 2024 --> Aug 2025 | Trial primary completion date: Aug 2024 --> Aug 2025
- ||| Anniko (penpulimab) / Akesobio, Sino Biopharm, Focus V (anlotinib) / Advenchen, Sino Biopharm
Trial completion, Trial completion date, Combination therapy, Metastases: PAAG: A Study of Penpulimab and Anlotinib Plus Nab-paclitaxel and Gemcitabine for Metastatic Pancreatic Cancer. (clinicaltrials.gov) - May 9, 2024
P2, N=66, Completed, Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Trial completion date: Aug 2024 --> Aug 2025 | Trial primary completion date: Aug 2024 --> Aug 2025 Recruiting --> Completed | Trial completion date: Dec 2024 --> May 2024
- ||||| irinotecan hydrochloride liposome injection (HR070803) / Jiangsu Hengrui Pharma
Enrollment change, Combination therapy, Metastases: HR070803 in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Advanced Pancreatic Cancer (clinicaltrials.gov) - May 8, 2024
P3, N=778, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Recruiting --> Completed | Trial completion date: Dec 2024 --> May 2024 N=522 --> 778
- ||||| Keytruda (pembrolizumab) / Merck (MSD), pembrolizumab/hyaluronidase (MK-3475A) / Merck (MSD)
Enrollment closed, Metastases: A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)-Japan Extension (clinicaltrials.gov) - May 8, 2024
P3, N=378, Active, not recruiting, Sponsor: Merck Sharp & Dohme LLC
N=522 --> 778 Recruiting --> Active, not recruiting
- | TheraCIM (nimotuzumab) / Daiichi Sankyo, Oncoscience, Biocon
New P2 trial: Nimotuzumab Plus AG in Pancreatic Cancer With Liver Metastasis (clinicaltrials.gov) - May 8, 2024
P2, N=30, Recruiting, Sponsor: Tianjin Medical University Cancer Institute and Hospital
- | Tyvyt (sintilimab) / Eli Lilly
New P2 trial, Combination therapy, Metastases: Safety and Efficacy of Neoadjuvant Immunochemotherapy in Elderly Patients With Resectable Esophageal Cancer (clinicaltrials.gov) - May 8, 2024
P2, N=68, Recruiting, Sponsor: Sichuan University
- | iparomlimab/tuvonralimab (PSB205) / Sound Biologics, Qilu Pharma
New P2 trial: QUEEN-Dream: QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk TNBC Breast Cancer (clinicaltrials.gov) - May 8, 2024
P2, N=73, Not yet recruiting, Sponsor: Fudan University
- | iparomlimab/tuvonralimab (PSB205) / Sound Biologics, Qilu Pharma
New P2 trial: QUEEN-Neo: QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk ER+/HER2- Breast Cancer (clinicaltrials.gov) - May 8, 2024
P2, N=76, Not yet recruiting, Sponsor: Fudan University
- Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci
Radiolabeled PD-L1 targeted nanobody 68Ga-THP-APN09 in predicting the efficacy of neoadjuvant immunotherapy combined chemotherapy in resectable non-small cell lung cancer (801B (Convention Center); In-Person) - May 8, 2024 - Abstract #SNMMI2024SNMMI_2139;
Recruiting --> Active, not recruiting After 2